RE:RE:RE:“Second mouse gets the cheese “October 2023 was about the same time that a decision was made not to proceed with the ONCY/ PanCan Phase 3 pancreatic cancer study using pelareorep + atezolizumab + chemotherapy. Instead PanCan had sponsored a Phase 3 study involving pelareorep + atezolizumab + mFOLFIRINOX.
These events happening at the same time that BioNTech/Genentech(Roche) initiated a Phase 2 with autogene cevumeran + atezolizumab + mFOLFIRINOX in October 2023, does not appears as coincidence, since most things happening with ONCY and its stock price also appears "managed".